

Bicycle Innovative molecules. Pipeline trials.

Pioneering a new, differentiated class of innovative medicines¹⁻³

Bicycle® molecules are a novel class of cancer therapeutics currently in development that are made from structurally constrained bicyclic peptides that can be readily conjugated to a payload.



Conjugated with:

Cytotoxin

OR

Radionuclide

OR

Bicycle® peptide

References: 1. Heinis C, et al. *Nat Chem Biol.* 2009;5(7):502-507. doi:10.1038/nchembio.184 2. Mudd GE, et al. *J Med Chem.* 2020;63(8):4107-4116. doi:10.1021/acs.jmedchem.9b02129 3. Eder M, et al. *Cancer Res.* 2019;79(4):841-852. doi:10.1158/0008-5472.CAN-18-0238 4. Sharma AK, et al. *Theranostics.* 2025;15(10):4229-4246. doi:10.7150/thno.106948 5. Eder A-C, et al. Presented at: American Association for Cancer Research (AACR) Annual Meeting 2025; April 25-30, 2025; Chicago, IL. Session 4601.

Building a robust pipeline of clinical trials

	TRIAL NAME	TREATMENT	INDICATIONS	PRECLINICAL	PHASE 1	PHASE 2	PHASE 3	RECRUITING
Zelenectide pevedotin (BT8009) Nectin-4-targeted Bicycle® Drug Conjugate comprising a peptide conjugated to MMAE via a linker	Duravelo-1 (BT8009-100) NCT04561362	zelenectide pevedotin ± pembrolizumab	Advanced solid tumors	PHASE 1/2				✓
	Duravelo-2 (BT8009-230) NCT06225596	zelenectide pevedotin ± pembrolizumab	1L mUC 2L+ mUC	PHASE 2/3				✓
	Duravelo-3 (BT8009-201) NCT06840483	zelenectide pevedotin	2L+ HR+/HER2- 2L+ TNBC	PHASE 2				✓
	Duravelo-4 (BT8009-202) NCT06933329	zelenectide pevedotin	2L+ squamous NSCLC 2L+ nonsquamous NSCLC	PHASE 2				
BT5528 EphA2-targeted Bicycle® Drug Conjugate comprising a peptide conjugated to MMAE via a linker	BT5528-100 NCT04180371	BT5528 ± nivolumab	Advanced solid tumors				PHASE 1/2	✓
BT7480 Nectin-4/CD137 Bicycle tumor-targeted immune cell agonist®	BT7480-100 NCT05163041	BT7480 ± nivolumab	Advanced solid tumors				PHASE 1/2	
⁶⁸Ga imaging agent	⁶⁸Ga-EphA2⁴	⁶⁸ Ga imaging agent	Advanced solid tumors	DISCOVERY				
	⁶⁸Ga-MT1-MMP⁵	⁶⁸ Ga imaging agent	Advanced solid tumors	IND-READY				

Product candidates are investigational only and are not approved medicines.

1L=first line; 2L+=second line or later; Ga=gallium; HER2=human epidermal growth factor receptor 2-negative; HR+=hormone receptor-positive; IND=investigational new drug; MMAE=monomethyl auristatin E; mUC=metastatic urothelial cancer; NSCLC=non-small cell lung cancer; TNBC=triple-negative breast cancer.